Health
J&J’s COVID-19 vaccine 66 per cent effective in trial – The Tribune India
The vaccine is 85 per cent effective in stopping severe disease and preventing hospitalisation
January 29
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large trial against multiple variants across three continents.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.
A high bar has been set by two authorised vaccines from Pfizer/BioNTech and Moderna,…
-
Business22 hours ago2 must-have ASX shares to buy for dividend income investors
-
General24 hours agoMontana’s house was gutted by an accidental fire. Then her landlord accused her of starting it
-
Business24 hours agoThe smartest ASX dividend stocks to buy with $5,000 right now
-
Noosa News11 hours agoWhat has the premier changed about the Queensland government logo? Take the Brisbane Times Quiz